Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)

By sjmartinez • March 8, 2024

Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024 Mar 7. doi: 10.1111/jdv.19925. Epub ahead of print. PMID: 38451052.

Tags: Dermatology, Publications

Immune activation and glycolytic responses to Cutibacterium acnes cell wall polysaccharides

Qin M, Evron E, Tran PT, Deng M, Nelson AM, Kim J, Agak GW. Immune activation and glycolytic responses to Cutibacterium acnes cell wall polysaccharides.[...]

Frailty in lung transplant recipients is associated with anemia and telomere dysfunction but independent of epigenetic age

Kapse B, Mohanty RP, Wax M, Gao Y, Tran L, Wolters PJ, Pellegrini M, Singer JP, Greenland JR. Frailty in lung transplant recipients is associated[...]

Toxic Epidermal Necrolysis-Like Acute Cutaneous Lupus Erythematosus Following an Upper Respiratory Infection

Yan MJ, Phan H, Hsu S, Kang Y, Yu Y. Toxic Epidermal Necrolysis-Like Acute Cutaneous Lupus Erythematosus Following an Upper Respiratory Infection. Cureus. 2025 Apr[...]